Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Saint-Prex, Switzerland:    This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin®

READ MORE

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Saint-Prex, Switzerland:   OPTIMISE study found a treat-to-target (T2T) management strategy in people with mild-to-moderate ulcerative colitis (M2M UC) being

READ MORE